Shipments of the antinausea agent Marinol (dronabinol) to "selected regional markets" began the week of July 14. The cannabinoid anti-emetic for cancer chemotherapy patients was approved in June 1985. However, the Drug Enforcement Agency did not complete rescheduling of the drug from Schedule I to Schedule II until April ("The Pink Sheet" April 7, T&G-2). Under a previously announced marketing agreement, Roxane will be responsible for final packaging, marketing and distribution of the drug.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.